Articles with public access mandates - Martha K. Terris, MDLearn more
Not available anywhere: 35
Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer
CA Whitney, LE Howard, SJ Freedland, AM DeHoedt, CL Amling, ...
Prostate cancer and prostatic diseases 22 (2), 252-260, 2019
Mandates: US National Institutes of Health
Association of obesity‐related hemodilution of prostate‐specific antigen, dihydrotestosterone, and testosterone
Z Klaassen, LE Howard, DM Moreira, GL Andriole Jr, MK Terris, ...
The Prostate 77 (5), 466-470, 2017
Mandates: US National Institutes of Health
Predictors of secondary treatment following biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database
DM Moreira, LL Bañez, JC Presti Jr, WJ Aronson, MK Terris, CJ Kane, ...
BJU international 105 (1), 28-33, 2010
Mandates: US National Institutes of Health
Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy
LL Bañez, L Sun, BJ Trock, M Han, AW Partin, WJ Aronson, MK Terris, ...
The Journal of urology 182 (2), 491-498, 2009
Mandates: US National Institutes of Health
First postoperative PSA is associated with outcomes in patients with node positive prostate cancer: Results from the SEARCH database
ML McDonald, LE Howard, WJ Aronson, MK Terris, MR Cooperberg, ...
Urologic Oncology: Seminars and Original Investigations 36 (5), 239. e17-239 …, 2018
Mandates: US National Institutes of Health
Preoperative predictors of blood loss at the time of radical prostatectomy: results from the SEARCH database
JC Lloyd, LL Banez, WJ Aronson, MK Terris, JC Presti, CL Amling, ...
Prostate Cancer and Prostatic Diseases 12 (3), 264-268, 2009
Mandates: US National Institutes of Health
Does early prostate‐specific antigen doubling time (ePSADT) after radical prostatectomy, calculated using PSA values from the first detectable until the first recurrence value …
AE Teeter, JC Presti Jr, WJ Aronson, MK Terris, CJ Kane, CL Amling, ...
BJU international 104 (11), 1604-1609, 2009
Mandates: US National Institutes of Health
Estimated blood loss as a predictor of PSA recurrence after radical prostatectomy: results from the SEARCH database
JC Lloyd, LL Bañez, WJ Aronson, MK Terris, JC Presti Jr, CL Amling, ...
BJU international 105 (3), 347-351, 2010
Mandates: US National Institutes of Health
Does early prostate specific antigen doubling time after radical prostatectomy, calculated prior to prostate specific antigen recurrence, correlate with prostate cancer …
AE Teeter, K Griffin, LE Howard, WJ Aronson, MK Terris, CJ Kane, ...
The Journal of Urology 199 (3), 713-718, 2018
Mandates: US National Institutes of Health
Competing risks of mortality among men with biochemical recurrence after radical prostatectomy
TJ Daskivich, LE Howard, CL Amling, WJ Aronson, MR Cooperberg, ...
The Journal of urology 204 (3), 511-517, 2020
Mandates: US Department of Defense, US National Institutes of Health
Diabetes predicts metastasis after radical prostatectomy in obese men: results from the SEARCH database.
C Wu, WJ Aronson, MK Terris, JC Presti, CJ Kane, CL Amling, ...
BJU international 111 (8), 2013
Mandates: Howard Hughes Medical Institute
Limitations of prostate specific antigen doubling time following biochemical recurrence after radical prostatectomy: results from the SEARCH database
RJ Hamilton, WJ Aronson, MK Terris, CJ Kane, JC Presti Jr, CL Amling, ...
The Journal of urology 179 (5), 1785-1790, 2008
Mandates: US National Institutes of Health
Statins are associated with increased biochemical recurrence after radical prostatectomy in diabetic men but no association was seen in men also taking metformin: results from …
A Aminsharifi, LE Howard, CL Amling, WJ Aronson, MR Cooperberg, ...
Clinical genitourinary cancer 17 (1), e140-e149, 2019
Mandates: US National Institutes of Health
Influence of sociodemographic factors on definitive intervention among low-risk active surveillance patients
RK Sayyid, L Klotz, JZ Benton, A Lodh, JH Lambert, P Woodruff, ...
Urology 155, 117-123, 2021
Mandates: US National Institutes of Health
HYAL4-V1/Chondroitinase (Chase) drives gemcitabine resistance and predicts chemotherapy failure in patients with bladder cancer
SL Hasanali, DS Morera, RR Racine, M Hennig, S Ghosh, LE Lopez, ...
Clinical Cancer Research 27 (15), 4410-4421, 2021
Mandates: US Department of Defense, US National Institutes of Health
Prostate weight and prostate cancer outcomes after radical prostatectomy: Results from the SEARCH cohort study
SK Barlow, T Oyekunle, JL Janes, AM De Hoedt, WJ Aronson, CJ Kane, ...
The Prostate 82 (3), 366-372, 2022
Mandates: US National Institutes of Health
Safety of concomitant therapy with radium‐223 and abiraterone or enzalutamide in a real‐world population
H Zhao, LE Howard, AM De Hoedt, MK Terris, CL Amling, CJ Kane, ...
The Prostate 81 (7), 390-397, 2021
Mandates: US National Institutes of Health
Obese men undergoing radical prostatectomy: Is robotic or retropubic better to limit positive surgical margins? Results from SEARCH
F Nik‐Ahd, LE Howard, WJ Aronson, MK Terris, Z Klaassen, ...
International Journal of Urology 27 (10), 851-857, 2020
Mandates: US National Institutes of Health
DOES BEING ON ADT ALTER THE ABILITY OF PSA AND PSADT TO PREDICT A POSITIVE BONE SCAN? RESULTS FROM THE SEARCH DATABASE: 860
D Moreira, W Aronson, M Terris, J Presti Jr, C Amling, C Kane, ...
Journal of Urology 183 (4), e335-e336, 2010
Mandates: US National Institutes of Health
Is time to castration resistant prostate cancer a potential intermediate end-point for time to metastasis among men initiating androgen deprivation therapy for non-metastatic …
Z Klaassen, L Howard, CJD Wallis, JL Janes, A De Hoedt, WJ Aronson, ...
Prostate Cancer and Prostatic Diseases 26 (1), 151-155, 2023
Mandates: US Department of Defense, US National Institutes of Health
Publication and funding information is determined automatically by a computer program